Difference between revisions of "Testicular cancer - historical"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s)...") |
|||
| Line 167: | Line 167: | ||
|[https://www.nejm.org/doi/full/10.1056/NEJM196501212720301 Brown & Kennedy 1965] | |[https://www.nejm.org/doi/full/10.1056/NEJM196501212720301 Brown & Kennedy 1965] | ||
| style="background-color:#ffffbe" |Non-randomized, <20 pts | | style="background-color:#ffffbe" |Non-randomized, <20 pts | ||
| + | |- | ||
| + | |[https://jamanetwork.com/journals/jama/article-abstract/339573 Ream et al. 1968] | ||
| + | | style="background-color:#91cf61" |Non-randomized | ||
|- | |- | ||
|} | |} | ||
| Line 173: | Line 176: | ||
===References=== | ===References=== | ||
# Brown JH, Kennedy BJ. Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med. 1965 Jan 21;272:111-8. [https://www.nejm.org/doi/full/10.1056/NEJM196501212720301 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14224214 PubMed] | # Brown JH, Kennedy BJ. Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med. 1965 Jan 21;272:111-8. [https://www.nejm.org/doi/full/10.1056/NEJM196501212720301 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14224214 PubMed] | ||
| + | # Ream NW, Perlia CP, Wolter J, Taylor SG 3rd. Mithramycin therapy in disseminated germinal testicular cancer. JAMA. 1968 Jun 17;204(12):1030-6. [https://jamanetwork.com/journals/jama/article-abstract/339573 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/5694748 PubMed] | ||
[[Category:Historical regimens]] | [[Category:Historical regimens]] | ||
Revision as of 01:32, 1 January 2019
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main testicular cancer page for current regimens.
7 regimens on this page
7 variants on this page
|
Adjuvant therapy for resectable disease
BVP
| back to top |
BVP: Bleomycin, Vinblastine, Platinol (Cisplatin)
PVB: Platinol (Cisplatin), Vinblastine, Bleomycin
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Williams et al. 1987 | Phase III (E) | Observation | Superior RFS |
Preceding treatment
Chemotherapy
28-day cycle for 2 cycles
References
- Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT, DeWys WD, Crawford ED. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med. 1987 Dec 3;317(23):1433-8. link to original article PubMed
Upfront therapy for disseminated disease
Bleomycin & Vinblastine
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Peckham et al. 1979 | Non-randomized |
Chemotherapy
References
- Peckham MJ, McElwain TJ, Barrett A, Hendry WF. Combined management of malignant teratoma of the testis. Lancet. 1979 Aug 11;2(8137):267-70. lnk to original article PubMed
BVP
| back to top |
BVP: Bleomycin, Vinblastine, Platinol (Cisplatin)
PVB: Platinol (Cisplatin), Vinblastine, Bleomycin
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Einhorn & Donohue 1977 | Non-randomized | ||
| Einhorn et al. 1981 | Phase III (C) | ABVP | Seems not superior |
| Garnick et al. 1983 | Non-randomized | ||
| Stoter et al. 1986 | Phase III (C) | Dose de-escalated PVB | Seems not superior |
| Williams et al. 1987 | Phase III (C) | BEP | Seems to have inferior OS |
Chemotherapy
21-day cycle for 4 cycles
Subsequent treatment
- Einhorn et al. 1981: Vinblastine maintenance versus no further treatment
- Garnick et al. 1983: Tumor-reductive surgery, then Cyclophosphamide & Doxorubicin
References
- Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293-8. link to original article PubMed
- Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med. 1981 Sep 24;305(13):727-31. link to original article PubMed
- Garnick MB, Canellos GP, Richie JP. Treatment and surgical staging of testicular and primary extragonadal germ cell cancer. JAMA. 1983 Oct 7;250(13):1733-41. link to original article PubMed
- Stoter G, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, Jones WG, van Oosterom AT, Vendrik CP, Spaander P, de Pauw M, Sylvester R. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1986 Aug;4(8):1199-206. link to original article PubMed
- Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987 Jun 4;316(23):1435-40. link to original article contains verified protocol PubMed
CISCA/VB
| back to top |
CISCA/VB: CISplatin, Cyclophosphamide, Adriamycin (Doxorubicin) alternating with Vinblastine & Bleomycin
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Fizazi et al. 2002 | Phase III (C) | Dose de-escalated CISCA/VB | Seems not superior |
| Culine et al. 2008 (T93MP) | Phase III (E) | BEP | Seems not superior |
Chemotherapy, CISCA portion
Chemotherapy, VB portion
References
- Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol. 2002 Jan;13(1):125-34. link to original article PubMed
- T93MP: Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol. 2008 Jan 20;26(3):421-7. link to original article contains verified protocol PubMed
Subsequent lines of therapy
Plicamycin monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Brown & Kennedy 1965 | Non-randomized, <20 pts |
| Ream et al. 1968 | Non-randomized |
Chemotherapy
References
- Brown JH, Kennedy BJ. Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med. 1965 Jan 21;272:111-8. link to original article PubMed
- Ream NW, Perlia CP, Wolter J, Taylor SG 3rd. Mithramycin therapy in disseminated germinal testicular cancer. JAMA. 1968 Jun 17;204(12):1030-6. link to original article PubMed